Longeveron Inc. Announces ELPIS II Topline Trial Results — Missed Endpoint

What Happened Longeveron Inc., a clinical-stage biotechnology company, filed an 8-K (Sept 23, 2026) disclosing a press release dated Sept 16, 2026 with topline results from ELPIS II, its Phase 2b trial of laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The trial did not meet the primary efficacy endpoint — change from baseline in right ventricular ejection fraction (RVEF) at Month 12. In the intent-to-treat population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p = 0.8336). The press release is attached to the filing as Exhibit 99.1.

Key Details

• Trial: ELPIS II, Phase 2b, laromestrocel as adjunct to Stage 2 surgery in infants with HLHS (n=40).
• Primary endpoint: Change from baseline in RVEF at Month 12 — result: LS mean difference −0.7 percentage points.
• Statistical details: 95% confidence interval −7.3 to 5.9; p = 0.8336.
• Filing: 8-K filed Sept 23, 2026; press release dated Sept 16, 2026 (Exhibit 99.1).

Why It Matters Missing the primary endpoint is a material clinical setback for Longeveron’s lead pediatric program because RVEF was the trial’s prespecified measure of benefit. For investors, this outcome may affect the program’s regulatory and development prospects and could influence the company’s valuation and capital needs. The 8-K provides topline results but does not detail next steps or additional analyses; investors should watch for follow-up disclosures from the company about further data, subgroup analyses, or changes to the development plan.